Advanced Asthma & the Role of Biologics: When Inhalers Aren't Enough

For most people with asthma, a combination of a controller inhaler and a rescue inhaler is enough to keep symptoms manageable. But for an estimated 5–10% of asthma patients, the standard approach simply doesn't cut it. Despite taking their medications as prescribed, these patients continue to experience frequent flare-ups, nighttime symptoms, emergency room visits, and a quality of life that falls far short of what it should be.

If this sounds familiar, you're not failing at managing your asthma — your asthma may just require a more advanced treatment strategy. That's where biologic therapies come in.

What Is Severe or Uncontrolled Asthma?

Asthma is classified as severe when it remains uncontrolled despite medium- to high-dose inhaled corticosteroids (ICS) combined with a long-acting beta-agonist (LABA) — the standard step-up therapy most pulmonologists try first. Signs that your asthma may be severe include:

• Using your rescue inhaler more than twice per week
• Waking up at night due to coughing, wheezing, or shortness of breath
• Needing oral steroids (like prednisone) two or more times per year
• Visiting the emergency room or being hospitalized for asthma attacks
• Avoiding activities, exercise, or social events because of breathing limitations
• Persistently reduced lung function on spirometry testing

Before escalating treatment, your pulmonologist will first ensure that your current medications are being used correctly (inhaler technique matters more than most patients realize), that you don't have overlapping conditions like acid reflux, vocal cord dysfunction, or chronic sinusitis mimicking asthma symptoms, and that environmental triggers are being properly controlled.

Understanding Asthma Subtypes: Why It Matters

One of the most important advances in asthma care over the past two decades has been the recognition that not all asthma is the same. What we once thought of as a single disease is actually a collection of different inflammatory pathways, each driven by different immune system mechanisms. Identifying which pathway is driving your asthma is the key to choosing the right biologic.

Type 2 (T2-High) Asthma

The most common subtype of severe asthma, T2-high asthma is driven by a specific arm of the immune system called the Type 2 inflammatory pathway. In these patients, the immune system overproduces certain signaling proteins — particularly interleukin-4 (IL-4), interleukin-5 (IL-5), and interleukin-13 (IL-13) — that cause airway inflammation, excess mucus, and bronchospasm.

T2-high asthma often overlaps with allergies, nasal polyps, eczema, and elevated blood eosinophils. Your doctor can identify it through a combination of blood tests (eosinophil count, total IgE) and FeNO testing — a simple breath test that measures fractional exhaled nitric oxide, a direct marker of airway inflammation.

Non-T2 (T2-Low) Asthma

A smaller subset of severe asthma patients have inflammation driven by different immune pathways (neutrophilic or paucigranulocytic). This type is less well understood and currently has fewer targeted therapies, though research is advancing rapidly. Biologics targeting T2-high inflammation are not effective for these patients, which is why accurate phenotyping matters so much.

What Are Biologic Therapies?

Biologics are a class of medications made from living cells that target specific molecules in the immune system. Unlike traditional asthma medications that broadly suppress inflammation or relax airway muscles, biologics work with precision — they block the exact proteins responsible for triggering and sustaining the inflammatory cascade in your airways.

Think of it this way: if your inhaled corticosteroid is a wide-angle sprinkler watering the entire lawn, a biologic is a surgical drip line delivering treatment precisely where the problem is.

Biologics for asthma are administered as injections, either at home with a self-injection pen or in a clinical setting, typically every 2–8 weeks depending on the medication. They are not rescue medications — they work by reducing the underlying inflammation over weeks to months, leading to fewer flare-ups, less need for oral steroids, and better day-to-day breathing.

Currently Approved Asthma Biologics

The FDA has approved several biologic therapies for severe asthma, each targeting a different part of the T2 inflammatory pathway:

Biologic	Target	Best For	Dosing
Omalizumab (Xolair)	IgE antibody	Allergic (IgE-driven) asthma	Every 2–4 weeks
Mepolizumab (Nucala)	IL-5	Eosinophilic asthma	Every 4 weeks
Benralizumab (Fasenra)	IL-5 receptor	Eosinophilic asthma	Every 8 weeks (after initial doses)
Dupilumab (Dupixent)	IL-4 & IL-13	Eosinophilic and/or high-FeNO asthma; also treats nasal polyps and eczema	Every 2 weeks
Tezepelumab (Tezspire)	TSLP (upstream cytokine)	Severe asthma across phenotypes, including some T2-low patients	Every 4 weeks
Itepekimab (Ebvallo) & others	IL-33 and other pathways	Newer agents in late-stage trials for broader asthma populations	Varies

Each medication has a different profile, and the right choice depends on your specific biomarkers, allergic history, other conditions (like nasal polyps or eczema), and insurance coverage. This is not a one-size-fits-all decision — it's a conversation between you and your pulmonologist based on your individual data.

Who Qualifies for Biologic Therapy?

Biologics are typically considered when a patient meets these criteria:

• Confirmed diagnosis of severe persistent asthma
• Poor control despite adherence to high-dose ICS/LABA therapy
• Correct inhaler technique verified by a clinician
• Comorbid conditions (reflux, sinusitis, obesity) have been addressed
• Biomarkers suggest a T2-high phenotype: elevated blood eosinophils (≥150–300 cells/μL), elevated FeNO (≥25 ppb), or elevated total IgE

Your PulmoCrit pulmonologist will perform a comprehensive workup including pulmonary function testing, FeNO measurement, blood work, and a thorough review of your asthma history before recommending a specific biologic.

What to Expect from Biologic Treatment

Patients starting biologics often want to know: how quickly will I feel better? The honest answer is that biologics are a slow build, not an overnight fix. Most patients begin to notice improvement within 4–12 weeks, though full benefit may take 3–6 months. What improvement looks like in practice:

• Fewer exacerbations — many patients go from multiple ER visits per year to zero
• Less oral steroid use — some patients are able to taper off prednisone entirely
• Better lung function — measurable improvements on spirometry
• Improved daily life — sleeping through the night, exercising without fear, fewer missed workdays
• Reduced rescue inhaler use — many patients find they rarely need their albuterol

Biologics are generally well tolerated. The most common side effects are mild injection-site reactions (redness or swelling that resolves within a day). Serious side effects are rare but will be discussed thoroughly with you before starting treatment.

The Role of FeNO Testing in Guiding Treatment

FeNO (fractional exhaled nitric oxide) testing has become one of the most valuable tools in managing severe asthma. This simple breath test measures the level of nitric oxide in your exhaled air — a direct indicator of eosinophilic airway inflammation.

At PulmoCrit, we use FeNO testing in several important ways:

• Diagnosis: Helping distinguish asthma from conditions that mimic it
• Phenotyping: Identifying whether your asthma is T2-high (biologic-eligible)
• Treatment selection: Guiding which biologic is most likely to work for you
• Monitoring response: Tracking whether your biologic is effectively reducing airway inflammation over time
• Medication adjustment: Helping determine if inhaled corticosteroid doses can safely be reduced

The test itself is effortless — you simply breathe out slowly into a handheld device for about 10 seconds. Results are available immediately, and no blood draw or preparation is needed.

What If You've Been Told "Your Asthma Is Just Hard to Control"?

If you've been managing asthma for years with limited success, it's worth asking whether your treatment approach has kept pace with the science. Biologic therapies have been available for over a decade now, yet many patients with severe asthma still haven't been evaluated for them. Common reasons include:

• Being managed by a primary care physician rather than a pulmonary specialist
• Never having FeNO testing or eosinophil levels checked
• Assuming that frequent flare-ups are "just how asthma is"
• Concerns about cost (most biologics have robust manufacturer assistance programs and are covered by many insurance plans)

The reality is that no one should accept poorly controlled asthma as normal. With today's treatment options, the vast majority of severe asthma patients can achieve significantly better control — and biologics are a major reason why.